These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34830179)

  • 1. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
    Jin X; Ding D; Yan Y; Li H; Wang B; Ma L; Ye Z; Ma T; Wu Q; Rodrigues DN; Kohli M; Jimenez R; Wang L; Goodrich DW; de Bono J; Dong H; Wu H; Zhu R; Huang H
    Mol Cell; 2019 Jan; 73(1):22-35.e6. PubMed ID: 30527665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
    Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
    Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
    Ruan H; Bao L; Tao Z; Chen K
    Cancer Immunol Res; 2021 Jul; 9(7):838-852. PubMed ID: 34011528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
    Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
    Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade.
    Rennier K; Shin WJ; Krug E; Virdi G; Pachynski RK
    Clin Cancer Res; 2020 Sep; 26(18):5019-5035. PubMed ID: 32605911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
    Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
    Wang Z; Zhang X; Li W; Su Q; Huang Z; Zhang X; Chen H; Mo C; Huang B; Ou W; Chen J; Zhao G; Chen L; Shao L
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
    Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
    J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
    Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
    Hays E; Bonavida B
    Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
    Ho M; Bonavida B
    Cells; 2024 May; 13(10):. PubMed ID: 38786085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.